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a b s t r a c t
The detailed mechanism driving the germinal center (GC) reaction to B cell lymphomagenesis has not
been clariﬁed. Thioredoxin interacting protein (TXNIP), also known as vitamin D3 up-regulated protein
1 which is an important tumor repressor, is involved in stress responses, redox regulation, and cellular
proliferation.Here,we report that TXNIPhas apotential role in the formationofGC inperipheral lymphoid
organs where B lymphocytes divide rapidly. First, we compared changes in GC from wild type mice and








Txnip mice. After immunization, Txnip mice exhibited higher expression level of BCL-6 and larger
percentage of GC B cells with the reduction in antibody production and plasma cell numbers. In addition,
Txnip−/− spleens had a much larger population which expressed Ki-67, a marker of cell proliferation,
in the red pulp border than WT spleens. Furthermore, the expression of BCL-6 was decreased in TXNIP
overexpressing cells and elevated in TXNIP deﬁcient cells. Taken together, we conclude that TXNIP may
contribute to the formation of GCs after immunization. During this process, TXNIP suppresses BCL-6
expression.
© 2010 Elsevier B.V. All rights reserved.
. Introduction
Thioredoxin interacting protein (TXNIP; also known as VDUP1)
as ﬁrst identiﬁed in 1,25-dihydroxyvitamin D3-treated HL-60
ells, a human leukemia cell line [1]. TXNIP not only induces oxida-
ive stress via interactingwith thioredoxin [2–5], but also regulates
ellular proliferation and the aging process. As a transcriptional
epressor, TXNIP physically interacts with other corepressors
ncluding promyelocytic leukemia zinc ﬁnger protein, Fanconi
nemia zinc ﬁnger protein and histone deacetylase 1 [6]. The
xpressionof TXNIP is frequently lost in tumor cell lines and tissues,
hereas the ectopic expression of TXNIP suppresses cellular pro-
iferation along with cell-cycle arrest at the G1 phase by inhibiting
AB1 [6,7].
Abbreviations: CSR, class-switch recombination; DNP, 2,4-dinitrophenyl; FDC,
ollicular dendritic cell; GC, germinal center; KLH, keyhole limpet hemocyanin; MC,
antle zone; PNA, lectin peanut agglutinin; SHM, somatic hypermutation; TD, T
ell-dependent; TI, T cell-independent.
∗ Corresponding author at: Department of Immunology, Korea Research Institute
f Bioscience and Biotechnology, Eoun-Dong 52, Yusong, Taejon 305-333, Republic
f Korea. Tel.: +82 42 860 4223; fax: +82 42 860 4593.
E-mail address: ipchoi@kribb.re.kr (I. Choi).
1 These authors contributed equally to this work.
TXNIP plays an important role in the growth regulation of 36
human T lymphocyte virus I (HTLV-I)-infected T cells. A signiﬁcant 37
lack of functional NK cells was found in Txnip−/− mice [8]. Dendritic 38
cells (DCs) derived from Txnip−/− mice are defective in activating T 39
cells [9]. TXNIP expression has been observed at different stages of 40
B cell development and in many cell lines [10]. 41
BCL-6 is a 95-kDa nuclear phosphoprotein that has a BTB/POZ 42
zinc ﬁnger DNA binding motif. Although BCL-6 is transcribed in 43
various cell types, its expression is mainly found in lymphocytes, 44
and it was abundantly expressed in germinal center (GC) B cells 45
and neoplastic B cells of GC origin [11–14]. BCL-6 deﬁcient mice 46
failed to form GCs during T cell-dependent immune responses and 47
thus displayed a fatal inﬂammatory disease [15,16]. GCs are the 48
sites of antigen-stimulated B cells proliferation and differentia- 49
tion that is aided by follicular dendritic cells (FDCs) and follicular 50
B helper T cells (TFHs) [17–19]. GCs are crucial for the develop- 51
ment of B cell responses including proliferation, apoptosis, somatic 52
hypermutation (SHM), selection for high-afﬁnitymaturation, class- 53
switch recombination (CSR), and differentiating into plasma cells 54
ormemory cells [18,20,21]. BCL-6 affects GC development via three 55
mechanisms. First, BCL-6 induces the GC to undergo SHM and CSR 56
by suppressing the activation of the apoptotic and cell-cycle arrest- 57
ing genes (p21, STAT2 and TP53) [22]. Second, BCL-6 represses 58
genes expression (CD69, STAT1, and CD80) which are involved in 59
165-2478/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
oi:10.1016/j.imlet.2010.02.002
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premature B cell activation by T cells or other signals prior to GC60
formation [23]. Third, BCL-6 represses BLIMP1 to inhibit B cell dif-61
ferentiation [24].62
Here, we present evidence that TXNIP regulates GC reactions by63
targetingBCL-6. TXNIP inhibited theexpressionofBCL-6, andTXNIP64
deﬁciency resulted in an increased immune response, especially in65
relation to GC reaction in mice, due to the increased expression of66
BCL-6.67
2. Materials and methods68
2.1. Mice and cell lines69
Txnip−/− mice were generated as previously described [8]. All70
mice were maintained under speciﬁc pathogen-free conditions71
with standard temperature and lighting. Mice were given food72
and water ad libitum. All studies were approved by the insti-73
tutional review board (KRIBB Institutional Animal Care and Use74
Committee/KRIBB-IACUC) and all procedures were performed in75
accordance with institutional guidelines for animal care. Human76
embryonic kidney-derived 293T cells were maintained in DMEM77
(Invitrogen) supplemented with 10% FBS (HyClone Laboratories)78
and antibiotics. The human Burkitt’s lymphoma cell lines (GC-79
derived B cell line) Raji and Ramos were maintained in RPMI80
(Invitrogen) supplemented with 10% FBS and antibiotics. All cell81
lines were obtained from the American Type Culture Collection.82
2.2. Immunization83
For induction of GC response, age-matched (6–8-week-old) WT84
and Txnip−/− male mice were immunized intraperitoneally with85
100g KLH (Calbiochem, 100g/mice) precipitated in alum and86
analyzed as described [25]. Brieﬂy, spleen was isolated from WT87
and Txnip−/− male mice at 10th day after immunization with88
KLH. For a kinetic analysis of GC B cells from WT and Txnip−/−89
spleen, GC B cells were examined by FACS at 0 day, 4 days, and90
10 days after immunization. For induction of secondary response,91
age-matched (6–8-week-old) WT and Txnip−/− male mice were92
immunized intraperitoneallywithDNP–Ficoll (25g/mice) inalum93
to elicit TI immune response or DNP–KLH (100g/mice) in alum to94
elicit TD immune response.95
2.3. Immunohistochemistry96
The spleen and lymph nodes were ﬁxed in 4% formaldehyde97
for 24h, embedded in parafﬁn, sectioned at 5m, and stained98
with hematoxylin and eosin. For immunostaining of tissue sec-99
tions, the sections were stained with primary antibodies. The100
following primary antibodies were used for labeling mouse tis-101
sue sections: anti-PNA antibody (Vector Laboratories), anti-BCL-6102
antibody (Santa Cruz Biotechnology); anti-CD3 antibody and103
anti-F4/80 antibody (Abcam); anti-Mac-3 antibody, anti-CD11b104
antibody, anti-B220 antibody, anti-FDCM1 antibody (BD PharMin-105
gen), and anti-Ki-67 antibody (Dako). Negative controls were106
treated identically but the primary antibodies omitted.107
2.4. Plasmid construction108
To generate the luciferase constructs for the human BCL-6 pro-109
moter pBCL-6-Luc (p135–1288), a 1154bp fragment spanning the110
3′ end of the human BCL-6 exon 1 and the 5′ region of intron 1111
(nucleotides +135 to +1288) was isolated from human lung DNA112
and cloned into the KpnI/HindIII sites of the pGL3-Basic luciferase113
reporter plasmid (Promega). Additional deletion mutants (p265–,114
436–, 436–, 696– and 703–1288) of the human BCL-6 promoter115
were constructed from pBCL-6-Luc (p135–1288) by PCR.
2.5. ELISA 116
Age-matched (6–8-week-old) WT mice and Txnip−/− mice 117
were immunized intraperitoneally with DNP–Ficoll (25g/mice; 118
Biosearch Technologies,) for TI immune response or DNP–KLH 119
(100g/mice; Biosearch Technologies) for TD immune response. 120
For primary response, sera were collected 10 days after primary 121
immunization. For secondary response, these two groups of mice 122
were boosted intraperitoneally with their original antigen 14 days 123
after second immunization, and sera were collected 30 days later. 124
Sera were then serially diluted, and added to 96-well ELISA plates 125
precoated with 50l DNP–BSA (10g/ml; Calbiochem) per well. 126
HRP-conjugated mouse IgM-, IgA-, and subclass IgG-speciﬁc anti- 127
bodies (Pierce) were used to detect the different antibody isotypes 128
and subclasses. 129
2.6. Luciferase reporter assay 130
Ramos cells were co-transfected with pBCL-6-Luc, its truncated 131
reporter plasmid, or TXNIP expression plasmid by microelectropo- 132
rator (Digital Bio Technology). A Renilla luciferase control vector 133
(Promega) was used to monitor the transfection efﬁciency. 134
2.7. Western blot analysis 135
Whole cell lysates of 293T cells co-transfected with plasmid 136
encoding HA-BCL-6 and HA-TXNIP were analyzed by western blot 137
using anti-BCL-6 antibody (Santa Cruz Biotechnology), anti-TXNIP 138
antibody (MBL), and anti--actin antibody (Sigma). For M and 139
S blots, whole cell lysates from total splenocytes were subject to 140
western blot with anti-IgM antibody (Sigma). 141
2.8. B cells proliferation assay 142
Splenocytes were harvested fromWT and Txnip−/− mice. B cells 143
were enriched by negative selection using a B Cell Isolation Kit 144
(Miltenyi Biotec). A total of 2×105 puriﬁed B cells were cultured 145
in triplicate wells for the indicated times in B cell media (RPMI 146
contains 100U/ml penicillin, 100mg/ml streptomycin, 50mg/ml 147
gentamycin, 2mM l-glutamine, 1mM sodium pyruvate, 50mM 2- 148
ME, and 20% FBS) and were stimulated with 10g/ml LPS (Sigma) 149
at 37 ◦C in a 5% CO2 incubator. The proliferation rate was then 150
monitored with Cell Counting Kit-8 (CCK-8) by utilizing WST-8 151
(Dojindo) as described previously [26]. In principle, as cultured cell 152
proliferates, there is an increase in activity of mitochondrial dehy- 153
drogenases, specially the succinate-tetrazolium reductase system. 154
WST-8 is reduced by dehydrogenases in cells to give a yellow 155
colored product (formazan). The amount of the formazan dye 156
generated by the activity of dehydrogenases in cells is directly pro- 157
portional to the number of living cells. 158
2.9. Flow cytometry and cell sorting 159
Puriﬁed B cells were collected by using a B Cell Isola- 160
tion Kit (Miltenyi Biotec). GC B cells (B220+ PNA+) and none 161
GC B cells (B220+ PNA−) were isolated from puriﬁed B cells 162
using a FACSAria (BD Biosciences) with a purity of at least 163
94%. The following antibodies were used for labeling cells and 164
were purchased from BD PharMingen or eBioscience except anti- 165
PNA-FITC (Vector Laboratories): anti-CD4-FITC; anti-IgM-FITC; 166
anti-IgG1-FITC; anti-CD38-FITC; anti-CD5-FITC; anti-CD11b-FITC; 167
anti-CD8-PE; anti-F4/80-PE; anti-MHCII-PE; anti-CD138-PE; anti- 168
CD11c-PE; anti-IgD-PE; anti-B220-PE-Cy7; anti-CD3-PE-Cy5; and 169
anti-strep-avidin-FITC. 170
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Fig. 1. The effects of TXNIP on GC formation are dependent on BCL-6 expression. Immunohistochemical analysis of PNA (A) and BCL-6 (B) in spleen and lymph node sections
from WT and Txnip−/− mice immunized with KLH. All immunohistochemical data through serial sectioning are representative of three WT and three Txnip−/− mice. (C)
Quantitative analysis of PNA or BCL-6 staining from WT or Txnip−/− mice. Quantitative analysis of PNA or BCL-6 was based on the ﬁve randomly highest density areas from
spleen and LN of WT or Txnip−/− mice. Data are shown as the mean± SD, and the statistical signiﬁcance was calculated from the Student’s t test between WT and Txnip−/−
samples. (D) After WT and Txnip−/− mice were immunized with KLH, total RNA was extracted from sorted splenic GC B cells. The expression of Txnip and BCL-6 mRNA in
GC B cells was examined by RT-PCR (top). The expression of Txnip and BCL-6 in nuclear extracts of splenic GC B cells was also examined by western blot (bottom). (E) Flow
cytometric analysis of splenic B cells from WT and Txnip−/− mice immunized with KLH. Cells were labeled with anti-B220-PE-Cy7 and anti-PNA-FITC. The numbers indicate
the percentage of B220+ PNA+ GC B cells. Data shown are representative dot plots of three independent experiments. Absolute numbers of GC B cells were determined before
and after immunization. The results are presented as the mean± SD of n=3–5 mice per genotype. **P≤0.01.
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2.10. q RT-PCR analysis171
Total RNA was extracted from cells using TRIzol (GibcoBRL).172
After reverse transcription, PCR reactionswere performedwith the173
following primers (5′–3′) were used for PCR:174















3.1. The effects of TXNIP on GC formation177
To examine the impact of TXNIP on the maturation and acti-178
vation of GC B cells, age-matched WT and Txnip−/− mice were179
immunized with TD antigens KLH. Immunohistochemical analy-180
sis for lectin peanut agglutinin (PNA) [27] demonstrated that the181
spleen and lymph nodes from Txnip−/− mice had a larger secondary182
follicle with GC structure than WT mice did (Fig. 1A). The expres-183
sion of BCL-6, mainly found in GC B cells, was also elevated in the 184
spleen and lymph nodes of Txnip−/− mice (Fig. 1B). There was no 185
positive strain in negative controls (Fig. S1) and the difference of 186
PNA and BCL-6 expression betweenWT and Txnip−/− micewas sta- 187
tistically signiﬁcant (Fig. 1C). Txnip−/− GC B cells exhibited much 188
stronger BCL-6 gene expression than WT GC B cells (Fig. 1D). In 189
line with these observations, the percentage of GC B cells (B220+ 190
PNA+ cells) was substantially higher in immunized Txnip−/− mice 191
than that in immunized WT mice (Fig. 1E). During GCs formation, 192
at the early stage (4 days after immunization), there is no differ- 193
ence between WT GC B cells and Txnip−/− GC B cells. However, at 194
the mature stage (10 days after immunization), the population of 195
GC B cells in Txnip−/− mice was much more than that in WT mice 196
(Fig S2). 197
In addition, immunohistochemical analysis of spleen sections 198
from Txnip−/− mice showed the normal proportions ofMac-3+ cells, 199
T cells, but the increased proportions of CD11b+ cells and FDCs 200
(FDCM1+) (Fig. S3A). When we analyzed the population of T cells, 201
macrophages, and DCs in spleen by ﬂow cytometry, there were no 202
signiﬁcant differences except for macrophages between WT and 203
Txnip−/− mice (Fig. S3B). We next examined B cell development in 204
Txnip−/− mice. TXNIP did not affect B cellmaturation (Fig. S4). Over- 205
all, these ﬁnding suggests that TXNIP is involved in GC formation. 206
3.2. The effects of TXNIP on B cell proliferation 207
Ki-67, which is a marker of cell proliferation, is preferentially 208
expressed during all active phases of the cell cycle (G1, S, G2, and 209
Fig. 2. The effect of TXNIP on cell proliferation. (A) Detection of Ki-67 expression in the spleen by immunohistochemistry. Staining for Ki-67 (brown) was performed withQ3
anti-Ki-67 antibody. (B) TUNEL analysis for detection of apoptosis in the spleen and lymph node. (C) The proliferation of splenic B cells from WT and Txnip−/− mice was
measured 10 days after immunization with PBS or KLH in alum using the CCK-8 Kit. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of the article.)
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M phase), but not in resting cells (G0 phase) [28]. Txnip−/− spleens210
had amuch larger population of Ki-67-positive cells in the red pulp211
border than WT spleens (Fig. 2A), indicating some Ki-67-positive212
cells in the red pulp proliferate actively on GC microenvironment.213
Meanwhile, TUNEL analysis showed that the number of apoptotic214
cells was similar in Txnip−/− and WT spleens (Fig. 2B). In CCK-8215
assay, the proliferation of splenic B cells from Txnip−/− mice was216
also elevated after immunized with KLH (Fig. 2C). Together, the217
data indicate that the larger and more numerous GC in Txnip−/−218
spleen mainly due to the fast proliferation of activated B cells, not219
intrinsically apoptotic effect of B cells.220
3.3. Role of TXNIP in plasma cell development221
We further identiﬁed GC-derived plasma cells and memory B222
cells. Ten days after immunized with KLH, WT mice showed an223
increased percentage of CD138+ B220+/− early short-lived plasma224
cells (Fig. 3A). When mouse splenic B cells were stimulated with225
LPS, they proliferated and differentiated into Ig-secreting cells in226
vitro [29]. After KLH-immunized splenocytes cells were stimulated227
with LPS for 4 days, the number of CD138+ B220+/− plasma cells228
increased in WT cultures is much stronger than that in Txnip−/−229
cultures (Fig. 3A). The level of IgM protein in Txnip−/− splenocytes230
was analyzed by western blot. Txnip−/− splenocytes expressed less231
Mand lessS comparedwithWT splenocytes (Fig. 3B, left).When232
the expression of heavy chain C-region genes fromWTand Txnip−/−233
spleen B cells was analyzed by RT-PCR, the production of class-234
switched germline IgG1 (1) and IgG3 (3) transcriptswas reduced235
in Txnip−/− B cells (Fig. 3B, right). Furthermore, there were con-236
sistently less circulating DNP-speciﬁc IgM, IgG1, IgA, and  light237
chain antibodies in the serum of Txnip−/− mice after immunization 238
with DNP–KLH or DNP–Ficoll (Fig. 3C). IgG3 showed the biggest 239
change between the response of mice immunized with KLH and 240
these immunized with Ficoll. In addition, light chain isotypes were 241
signiﬁcantly reduced. 242
3.4. TXNIP suppresses BCL-6 expression 243
To clarify whether TXNIP regulates GC response via BCL-6, we 244
next determined the effects of TXNIP on BCL-6 expression. The 245
transfection of cells with a TXNIP expression plasmid resulted in 246
the dose-dependent reduction in BCL-6 expression and a concur- 247
rent increase in BLIMP1 expression (Fig. 4A). Transfecting Raji cells 248
with a TXNIP expression plasmid also resulted in a dose-dependent 249
reduction in BCL-6 expression (Fig. 4B). Next, the effect of TXNIP on 250
the activity of the human BCL-6 promoter was tested. It was found 251
that TXNIP repressed BCL-6 promoter activity in a dose-dependent 252
manner (Fig. 4C). 253
4. Discussion 254
TXNIP mRNA was induced in a cell density-dependent fashion 255
concomitantly with the G0/G1 arrest [6]. The hyperproliferation of 256
Txnip−/− GC B cells indicated that TXNIP is important in regulat- 257
ing GC B cell division. In addition, Txnip−/− GC B cells showed the 258
increased BCL-6 gene expression. So far, the exactmechanisms that 259
regulate BCL-6 expression during GC formation are not yet fully 260
understood [14,30]. These reports made us investigate whether 261
TXNIP could directly regulate BCL-6 expression and affect GC for- 262
mation by modulating immune responses in GCs. 263
Fig. 3. B cell differentiation and immune responses in Txnip−/− mice. (A) The percentage of CD138+ B220+ cells was evaluated in the gated lymphocyte population in
splenocytes from WT and Txnip−/− mice before or after LPS treatment. The results are representatives of three independent experiments. (B) Cell lysates from splenocytes
cultured for 4 days in the presence of LPS were analyzed by western blot to detectM andS (left). Transcripts of class-switched germline IgG1, IgG3 and IgE in splenocytes
from WT and Txnip−/− mice were detected with RT-PCR (right). (C) WT and Txnip−/− mice were immunized with DNP–KLH (left) or DNP–Ficoll (right). Sera were collected
before immunization or on day 14 after secondary immunization. Secreted IgM, IgG1, IgG2a, IgG2b, IgA, and  or  chain antibodies were evaluated by ELISA. The data are
expressed as the mean± SD of three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001.
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Fig. 4. BCL-6 is repressed by TXNIP. (A) RT-PCR analysis of BLIMP1, BCL-6, and TXNIP mRNA expression in 293T cells transfected with an HA-TXNIP-expressing plasmid.
(B) Western blot analysis of Raji cells co-transfected with HA-BCL-6- and HA-TXNIP-expressing plasmids. (C) Ramos cells were co-transfected with the full-length BCL-6
promoter reporter plasmid and a TXNIP expression plasmid. Data are repressed as the mean± SD of triplicate determinations.
First, we found that Txnip−/− mice have more GCs in spleen and264
LN sections after immunization with KLH. Txnip−/− spleens had265
more CD11b positive cells – macrophages (CD11b+/F4/80+) and266
FDCM1 positive cells (FDCs). A large population of macrophages267
that usually highly proliferate in red pulp are thought to be impor-268
tant to regulate antigen trafﬁcking into the red and white pulp269
spaces [31]. Antigen trapped in the form of immune complexes is270
localized on FDCs resident within the follicle and, together with T271
follicular helper (TFH cells), drives rapid B cell proliferation to form272
GCs. Increased proportions of macrophages (CD11b positive cells)273
in spleen from Txnip−/− miceandamuch largerpopulationofKi-67-274
positive cells in the red pulp border of Txnip−/− spleens suggest that275
macrophages act as Ki-67-positive cells proliferating massively in276
the red pulp to regulate GC microenvironment. Increased FDCs in277
Txnip−/− spleens could also explain the expansion of GC in Txnip−/−278
mice.279
BCL-6 induces SHM in the dark zone of the GC. IRF4 controls280
plasma cell differentiation and CSR in the light zone of the GC. AID281
is critical in both processes, and XBP1 and BLIMP1 are involved in282
plasmacell differentiation [23]. After immunization, the expression283
level of BCL-6 in Txnip−/− splenic GC B cells was elevated, further284
indicating that TXNIP represses BCL-6 expression in the GC region.285
The reduction in BLIMP1 expression in Txnip−/− splenic GC B cells286
demonstrates the inﬂuence of TXNIP in plasma cell differentiation.287
Activated B cells undergo rounds of mutation and selection288
for higher afﬁnity mutants in the GC, resulting in high-afﬁnity289
antibody-secreting plasma cells and high-afﬁnity memory B cells.290
Previous studies have suggested that the down-regulation of BCL-6291
controls human plasma cell differentiation [32]. The reduction in292
thenumberofCD138+ B220− plasmacells inTxnip−/− mice suggests293
that TXNIP induces plasma cell differentiation. In Txnip−/− mice, the294
class-switch induction was partially impaired, resulting in lower295
level of DNP-speciﬁc IgM, IgG1, IgA, and  light chain antibodies296
in the serum (Fig. 3C). Therefore, the repression of BCL-6 by TXNIP297
would be beneﬁcial for maintaining plasma cell differentiation.298
TounderstandhowTXNIP regulates BCL-6 expressionduringGC299
reaction in detail, more study about molecular mechanism of sup-300
pressing BCL-6 expression by TXNIP is required. The mouse BCL-6 301
promoter has previously been partially characterized and com- 302
pared with human BCL-6 promoter [33]. A GC-rich 200-nt region 303
upstream of the major transcription start site was shown to con- 304
tain BCL-6 promoter activity in both human and mouse B cells. 305
Specially, one Rel/NF-B (from 172 to 178) and two STAT bind- 306
ing sites (from 216 to 239 and from 246 to 259) are within this 307
region of both human and mouse BCL-6 promoter. Considering 308
the Rel/NF-B sites are functionally important in BCL-6 promoter 309
assays, the relative importance of each of Rel/NF-B in control- 310
ling BCL-6 expression in B cells in vivo needs to be determined. 311
JunD/AP-1 also is reported as crucial molecules inducing high BCL- 312
6 expression in mouse GC B cells [33]. AP-1 DNA binding activity 313
was inhibited in Txnip−/−ﬁbroblast cells [7], suggesting that TXNIP 314
may repress BCL-6 expression via interacting with AP-1 in GC B 315
cells. 316
In conclusion, we found that TXNIP controls GC formation by 317
inhibiting BCL-6 expression. Based on our current understanding 318
of the role of BCL-6 in the programming of GCs and in the patho- 319
genesis of B cell lymphomas, an incisive insight of the cross-talk 320
between TXNIP and BCL-6 will contribute to overall understand- 321
ing of the unique physiology of GC B cells and diffuse large B cell 322
lymphomagenesis. 323
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